Core Viewpoint - Univest Securities, LLC has successfully closed a public offering of approximately $15 million for Globavend Holdings Limited, an emerging e-commerce logistics provider [1][4]. Group 1: Offering Details - The offering consists of 21,739,130 ordinary shares or pre-funded warrants, each sold with one Series A Warrant at an initial exercise price of $0.69 and one Series B Warrant at an initial exercise price of $1.173 [2]. - The purchase price for each ordinary share and accompanying warrants is $0.69, while the pre-funded warrants are priced at $0.689 [3]. - The gross proceeds to Globavend from this offering are approximately $15 million before deducting fees and expenses [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for capital expenditures, increasing operating capacity, working capital, general corporate purposes, purchasing warehouses, and potential mergers and acquisitions [4]. Group 3: Company Overview - Globavend Holdings Limited provides end-to-end logistics solutions primarily for enterprise customers in Hong Kong, Australia, and New Zealand, facilitating B2C transactions [9]. - The company offers integrated cross-border logistics services, including parcel drop-off, consolidation, air-freight forwarding, customs clearance, and final delivery [9].

Core Viewpoint - Ascent Solar Technologies, Inc. has announced a public offering of 1,000,000 shares of common stock and warrants, aiming to raise approximately $2.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with the same price for pre-funded warrants and accompanying warrants [1]. - The warrants will have an exercise price of $2.00 per share, are immediately exercisable, and will expire five years from the issuance date [1]. - The closing of the offering is anticipated around June 30, 2025, pending customary closing conditions [1]. Group 2: Financial Aspects - The expected gross proceeds from the offering are $2.0 million before deducting fees and expenses [2]. - The net proceeds will be allocated for working capital, product development, general administrative expenses, and other corporate purposes [2]. Group 3: Company Background - Ascent Solar Technologies is recognized for its innovative, high-performance, flexible thin-film solar panels, supported by 40 years of R&D and 15 years of manufacturing experience [5]. - The company's photovoltaic modules have been utilized in various applications, including space missions and commercial construction [5]. - The research and development center, along with a 5-MW production facility, is located in Thornton, Colorado [5].

Core Viewpoint - Lifeward Ltd. has successfully closed a public offering of 4,000,000 ordinary shares and accompanying warrants, raising approximately $2.6 million in gross proceeds, which will be used for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering price was set at $0.65 per ordinary share and associated ordinary warrant, with the warrants having an exercise price of $0.65 and expiring five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. - The potential additional gross proceeds from the exercise of the ordinary warrants, if fully exercised, could amount to another $2.6 million [3]. Group 2: Company Overview - Lifeward Ltd. is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, focusing on rehabilitation and recovery [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, with a mission to drive innovation in the field of physical rehabilitation [6].

Core Viewpoint - CorMedix Inc. plans to offer and sell $85.0 million of its common stock in an underwritten public offering, with a potential additional 15% option for underwriters [1][2] Group 1: Offering Details - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - RBC Capital Markets is acting as the sole bookrunner for the offering [2] - The net proceeds will be used for general corporate purposes, including working capital and research expenses [2] Group 2: Regulatory Information - The securities are being offered under a shelf registration statement filed with the SEC on May 6, 2024, and declared effective on May 22, 2024 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on their website [4] Group 3: Company Overview - CorMedix is focused on developing therapeutic products for life-threatening conditions, with its lead product DefenCath® approved by the FDA on November 15, 2023 [6] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [6] - The company plans to commence clinical studies in Total Parenteral Nutrition and Pediatric populations in 2025 [6]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Viewpoint - Kratos Defense & Security Solutions, Inc. has announced an underwritten offering of 12,987,013 shares of common stock at a price of $38.50 per share, aiming to raise approximately $483.75 million in net proceeds for various strategic initiatives [1][2]. Group 1: Offering Details - The offering price is set at $38.50 per share, with expected net proceeds of approximately $483,750,000 after underwriting discounts and commissions [1]. - Kratos has granted underwriters a 30-day option to purchase an additional 1,948,052 shares [1]. - The offering is anticipated to close on June 27, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will be utilized for investments and capital expenditures to support national security priorities, including existing programs and high-probability pipeline opportunities [2]. - Funds will also be allocated for targeted acquisitions and general corporate purposes, including debt repayment and offering-related expenses [2]. Group 3: Management and Regulatory Information - Baird, RBC Capital Markets, Truist Securities, and Raymond James are acting as joint book-running managers for the offering, with additional co-managers involved [3]. - The offering is conducted under an automatic shelf registration statement filed with the SEC, which became effective on February 21, 2024 [4].

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Group 1 - SeaStar Medical Holding Corporation announced a public offering of 6,153,847 shares of common stock at a price of $0.65 per share, with potential additional gross proceeds of up to $4 million from short-term warrants [1][4] - The Series A warrants will expire in five years, while the Series B short-term warrants will expire in 18 months, both having an exercise price of $0.65 per share [2] - The offering is expected to close around June 23, 2025, pending customary closing conditions [2] Group 2 - H.C. Wainwright & Co. is the exclusive placement agent for the offering [3] - The gross proceeds from the offering are anticipated to be approximately $4 million before deducting fees and expenses [4] - The net proceeds will be used for general corporate purposes [4] Group 3 - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product QUELIMMUNE approved by the FDA in 2024 for acute kidney injury in pediatric patients [7] - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process [7] - SeaStar is conducting a pivotal trial for its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [7]

Core Viewpoint - Biomea Fusion, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $40 million before expenses, with the offering expected to close on June 20, 2025 [1][2]. Group 1: Offering Details - The offering consists of 19,450,000 shares of common stock and accompanying warrants, along with pre-funded warrants for an additional 550,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrant is set at $2.00, while the pre-funded warrant and accompanying warrant are priced at $1.9999 [1]. - Underwriters have a 30-day option to purchase up to an additional 3,000,000 shares and/or warrants at the public offering price [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $40 million, excluding any additional shares or warrants purchased by underwriters [2]. - The offering is subject to customary closing conditions and is anticipated to close on June 20, 2025 [2]. Group 3: Management and Regulatory Information - Jefferies is acting as the sole book-running manager for the offering [3]. - The securities are being offered under an effective shelf registration statement previously filed with the SEC [3].